Associations of MTA1 expression with CT features, pathology and prognosis of elderly patients with non-small cell lung cancer

Yang,Ning; Li,Chuanming; Han,Xiao; Feng,Zhihua; Qiu,Feng; Han,Junqing

doi:10.3892/ol.2020.12034

Associations of MTA1 expression with CT features, pathology and prognosis of elderly patients with non-small cell lung cancer

Authors:
- Ning Yang
- Chuanming Li
- Xiao Han
- Zhihua Feng
- Feng Qiu
- Junqing Han
View Affiliations

Affiliations: Tumor Research and Therapy Center, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250021, P.R. China, Department of Pain Management, Jiading Hospital of Traditional Chinese Medicine, Shanghai 201800, P.R. China, Department of Experiment, Tumor Hospital Affiliated to Guangxi Medical University, Nanning, Guangxi 530021, P.R. China, Department of Proctology, Jiading Hospital of Traditional Chinese Medicine, Shanghai 201800, P.R. China, Department of Pain Management, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong 250021, P.R. China
Published online on: August 28, 2020 https://doi.org/10.3892/ol.2020.12034
Article Number: 172

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Associations of metastasis-associated protein 1 (MTA1) expression with computed tomography (CT) features, pathology and prognosis of elderly patients with non‑small cell lung cancer (NSCLC), and its clinical significance were explored. A total of 98 elderly patients with NSCLC were selected and underwent CT examination. The expression of MTA1 in carcinoma tissues and para-carcinoma normal tissues was detected via immunohistochemistry, and its associations with CT features, pathology and prognosis were analyzed. The results manifested that the expression of MTA1 in carcinoma tissues was significantly higher than that in para-carcinoma normal tissues, and it was associated with the degree of differentiation, stage and lymph node metastasis (P<0.05). Besides, the high expression of MTA1 was also related to the spicule sign, pleural indentation and lymph node metastasis (P<0.05) as well as the CT perfusion parameter capillary permeability (PMB) (P<0.05), but not to blood volume (BV), blood flow (BF) or time to peak (TTP). Moreover, the patients with high expression of MTA1 had significantly shorter survival time and a remarkably lower 5-year survival rate than those with low expression of MTA1 (P<0.05). In conclusion, MTA1 plays a certain role in the occurrence and development of NSCLC in elderly patients and has an association with their prognosis, which can provide references for the treatment and prognosis of NSCLC, with important clinical significance.

View Figures

View References

1	Jamal-Hanjani M, Wilson GA, McGranahan N, Birkbak NJ, Watkins TBK, Veeriah S, Shafi S, Johnson DH, Mitter R, Rosenthal R, et al TRACERx Consortium, : Tracking the evolution of non-small-cell lung cancer. N Engl J Med. 376:2109–2121. 2017. View Article : Google Scholar : PubMed/NCBI
2	Liu L, Zhou XY, Zhang JQ, Wang GG, He J, Chen YY, Huang C, Li L and Li SQ: LncRNA HULC promotes non-small cell lung cancer cell proliferation and inhibits the apoptosis by up-regulating sphingosine kinase 1 (SPHK1) and its downstream PI3K/Akt pathway. Eur Rev Med Pharmacol Sci. 22:8722–8730. 2018.PubMed/NCBI
3	Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, Ou SI, Pérol M, Dziadziuszko R, Rosell R, et al ALEX Trial Investigators, : Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med. 377:829–838. 2017. View Article : Google Scholar : PubMed/NCBI
4	Rotow J and Bivona TG: Understanding and targeting resistance mechanisms in NSCLC. Nat Rev Cancer. 17:637–658. 2017. View Article : Google Scholar : PubMed/NCBI
5	Hendriks LEL and Dingemans AC: Heat shock protein antagonists in early stage clinical trials for NSCLC. Expert Opin Investig Drugs. 26:541–550. 2017. View Article : Google Scholar : PubMed/NCBI
6	Ma K, Fan Y, Dong X, Dong D, Guo Y, Wei X, Ning J, Geng Q, Wang C, Hu Y, et al: MTA1 promotes epithelial to mesenchymal transition and metastasis in non-small-cell lung cancer. Oncotarget. 8:38825–38840. 2017. View Article : Google Scholar : PubMed/NCBI
7	Zhu X, Guo Y, Li X, Ding Y and Chen L: Metastasis-associated protein 1 nuclear expression is associated with tumor progression and clinical outcome in patients with non-small cell lung cancer. J Thorac Oncol. 5:1159–1166. 2010. View Article : Google Scholar : PubMed/NCBI
8	Hofer MD, Tapia C, Browne TJ, Mirlacher M, Sauter G and Rubin MA: Comprehensive analysis of the expression of the metastasis-associated gene 1 in human neoplastic tissue. Arch Pathol Lab Med. 130:989–996. 2006.PubMed/NCBI
9	Sasaki H, Moriyama S, Nakashima Y, Kobayashi Y, Yukiue H, Kaji M, Fukai I, Kiriyama M, Yamakawa Y and Fujii Y: Expression of the MTA1 mRNA in advanced lung cancer. Lung Cancer. 35:149–154. 2002. View Article : Google Scholar : PubMed/NCBI
10	Swensen SJ: CT screening for lung cancer. AJR Am J Roentgenol. 179:833–836. 2002. View Article : Google Scholar : PubMed/NCBI
11	Goss G, Tsai CM, Shepherd FA, Ahn MJ, Bazhenova L, Crinò L, de Marinis F, Felip E, Morabito A, Hodge R, et al: CNS response to osimertinib in patients with T790M-positive advanced NSCLC: Pooled data from two phase II trials. Ann Oncol. 29:687–693. 2018. View Article : Google Scholar : PubMed/NCBI
12	Jagadish N, Parashar D, Gupta N, Agarwal S, Sharma A, Fatima R, Suri V, Kumar R, Gupta A, Lohiya NK, et al: A novel cancer testis antigen target A-kinase anchor protein (AKAP4) for the early diagnosis and immunotherapy of colon cancer. OncoImmunology. 5:e10789652016. View Article : Google Scholar : PubMed/NCBI
13	Shi Y, Sun Y, Yu J, Ding C, Wang Z, Wang C, Wang D, Wang C, Wang Z, Wang M, et al: China experts consensus on the diagnosis and treatment of advanced stage primary lung cancer (2016 Version). (In Chinese). View Article : Google Scholar
14	Cui Y, Zhang F, Zhu C, Geng L, Tian T and Liu H: Upregulated lncRNA SNHG1 contributes to progression of non-small cell lung cancer through inhibition of miR-101-3p and activation of Wnt/β-catenin signaling pathway. Oncotarget. 8:17785–17794. 2017. View Article : Google Scholar : PubMed/NCBI
15	Wang Q, Wang Q, Wang SF, Jiao LJ, Zhang RX, Zhong Y, Zhang J and Xu L: Oral Chinese herbal medicine as maintenance treatment after chemotherapy for advanced non-small-cell lung cancer: A systematic review and meta-analysis. Curr Oncol. 24:269–276. 2017. View Article : Google Scholar
16	Vesel M, Rapp J, Feller D, Kiss E, Jaromi L, Meggyes M, Miskei G, Duga B, Smuk G, Laszlo T, et al: ABCB1 and ABCG2 drug transporters are differentially expressed in non-small cell lung cancers (NSCLC) and expression is modified by cisplatin treatment via altered Wnt signaling. Respir Res. 18:522017. View Article : Google Scholar : PubMed/NCBI
17	Jia QP, Yan CY, Zheng XR, Pan X, Cao X and Cao L: Upregulation of MTA1 expression by human papillomavirus infection promotes CDDP resistance in cervical cancer cells via modulation of NF-κB/APOBEC3B cascade. Cancer Chemother Pharmacol. 83:625–637. 2019. View Article : Google Scholar : PubMed/NCBI
18	Bui-Nguyen TM, Pakala SB, Sirigiri DR, Martin E, Murad F and Kumar R: Stimulation of inducible nitric oxide by hepatitis B virus transactivator protein-HBx requires MTA1 coregulator. J Biol Chem. 292:47652017. View Article : Google Scholar : PubMed/NCBI
19	Li HS, Lv RQ and Liu L: Correlation of CT indicators of NSCLC and pathological features and the expression level of p53 and c-myc. Eur Rev Med Pharmacol Sci. 22:135–141. 2018.PubMed/NCBI
20	Lee J, Cui Y, Sun X, Li B, Wu J, Li D, Gensheimer MF, Loo BW Jr, Diehn M and Li R: Prognostic value and molecular correlates of a CT image-based quantitative pleural contact index in early stage NSCLC. Eur Radiol. 28:736–746. 2018. View Article : Google Scholar : PubMed/NCBI
21	Abel S, Hasan S, White R, Schumacher L, Finley G, Colonias A and Wegner RE: Stereotactic ablative radiotherapy (SABR) in early stage non-small cell lung cancer: Comparing survival outcomes in adenocarcinoma and squamous cell carcinoma. Lung Cancer. 128:127–133. 2019. View Article : Google Scholar : PubMed/NCBI
22	Carrascosa P and Capunay C: Myocardial CT perfusion imaging for ischemia detection. Cardiovasc Diagn Ther. 7:112–128. 2017. View Article : Google Scholar : PubMed/NCBI
23	Chu LL, Knebel RJ, Shay AD, Santos J, Badawi RD, Gandara DR and Knollmann FD: CT perfusion imaging of lung cancer: Benefit of motion correction for blood flow estimates. Eur Radiol. 28:5069–5075. 2018. View Article : Google Scholar : PubMed/NCBI